Icon
+91 94997 68112
Login Register

Toviaz - (4 mg, 8mg, Tablet, Extended Release)

FESOTERODINE FUMARATE Pfizer
4 mg, 8mg, Tablet, Extended Release
Less Than $1000 mn
More Than 5
More Than 5
More Than 5
Less Than 5
More Than 5
More Than 5
Used to treat overactive bladder with symptoms of urinary frequency, urgency, and incontinence
Yes
*****, ******, *****, ********, *****, ******, ***** *** ********* **** ** ** *** **** ***** **** ***** * **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****). ***** ******, ***** *** ****** **** ***** **** ** **** *** **** ******* *** **** ************ *********. *** *** ********* ****** ******, ********, ******, ******, ***** ******** * ********** **** ****** ***** *** ***** ** ********** *** *** *****. ***** *** ***** ***** ** ****** ** ****** ******* **** ******* '***, '*** *** '*** *** ***** *** ********* ** ******, ********, ******, ******, ***** . **** ***** ********* ****** ***** *** ****** ****** **** *, ****. ******* *****, ******, ******, *********, ***** *** ***** ******* * ********** ***** ** *** ******* ** ****** ***** ********* ***** ****** **** **** ****** **** *, ****. ******* *** ** ***** **** ********, ******, *******, *****, *******, ***, ******, ********* ******** ********* *********. ***** ** *** ****** ** **** ** ****** ** ***, ******* *** ******* ****** ***** ********* **** *** ********* ********. **** ***** ** *****'*, ********* *** ******* **** ***** * **** ** *** **** ************ ********. ********** *** ********* **** ** *****'*, ********* *** ******* ** ****.
Toviaz Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
****** ****** *****(**** ** **) ****** *****(**** ** **) ******* ****** *****(**** ** **) ******* ******* ******* *******
***** ******* ******* ******* ******* ******* ******* ******* *******
***** ****** ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** **, **** ******* ********* ******** *** ****** **** ****
***** *** \ ** *** **, **** ******* ******** ******** ** *** **, ****
***** ****** *** \ ** *** **, **** ******* ******** ******** ** *** *, ****
  1. *** **, **** : ***** *** ****** ******** ****** ***** ***** **** ** **** *******'*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  2. *** **, **** : ****** ***** **** ******* ***** *** ****** ** ******** ***** ** ********.
  3. *** **, **** : *****, ********, *****, ******, ***** *** *********, ****** ******** ****** ***** ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  4. *** **, **** : ****** ***** * **** ******* *****, ********, *****, ******, *****,****** *** ********* ** ******** ***** ** ********.
  5. *** **, **** : ****** *** ****** ******** ***** ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  6. *** **, **** : ****** ***** * **** ******* ****** *** ****** ** ******** ***** ** ********.
  7. *** **, **** : ****** ***** * **** ******* ***** ** ******** ***** ** ******** ** ***** ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  8. *** *, **** : ********** *** ********* **** *** *** ********* ****** ******, ********, ******, ******, *****.
  9. *** **, **** : ***** ***** ** ****** ** ****** ** ****** *** ******* '*** *** '*** ** ***** *** ********* ** ******, ********, ******, ******.
  10. *** **, **** : ***** ***** ****** '*** ** ***** *** ********* ** ******, ********, ******, ******.
  11. *** **, **** : ****** ***** * **** ******* ** *****'* ** ** *****'* ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  12. *** *, **** : ********** *** ********* **** ** *****'*.
  13. *** **, **** : ****** ***** * **** ******* ********* ** ********* ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  14. *** *, **** : ********** *** ********* **** *********.
  15. *** *, **** : ****** ***** * **** ******* ******* ** ******* ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  16. *** *, **** : ********* *** ********* **** *******.
  17. *** **, **** : ***** ***** ******* '***, '***, '***, '*** ** ***** *** ********* ** *****. ***** ******** *** ******** ** ******* *******.
  18. *** **, **** : ********** *** ********* **** *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.